RecruitingDrug trialStudy of GV20-0251 in Participants With Solid Tumor MalignanciesThis is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.